abrdn Life Sciences Investors (NYSE:HQL) Sets New 1-Year High – Time to Buy?

abrdn Life Sciences Investors (NYSE:HQL)’s stock price reached a new 52-week high during trading on Thursday . The company traded as high as $21.42 and last traded at $21.3610, with a volume of 23881 shares. The stock had previously closed at $21.24.

abrdn Life Sciences Investors Stock Down 0.0%

The stock’s fifty day simple moving average is $19.19 and its 200-day simple moving average is $17.84.

abrdn Life Sciences Investors Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 30th. Stockholders of record on Monday, August 24th will be given a $0.62 dividend. This represents a $2.48 dividend on an annualized basis and a dividend yield of 11.7%. The ex-dividend date is Monday, August 24th.

Institutional Investors Weigh In On abrdn Life Sciences Investors

A number of large investors have recently added to or reduced their stakes in HQL. KPP Advisory Services LLC grew its position in abrdn Life Sciences Investors by 2.7% during the second quarter. KPP Advisory Services LLC now owns 25,251 shares of the company’s stock worth $505,000 after buying an additional 660 shares in the last quarter. 180 Wealth Advisors LLC raised its holdings in abrdn Life Sciences Investors by 2.2% in the 2nd quarter. 180 Wealth Advisors LLC now owns 152,829 shares of the company’s stock valued at $3,058,000 after acquiring an additional 3,271 shares in the last quarter. NewEdge Advisors LLC lifted its position in shares of abrdn Life Sciences Investors by 17.6% during the 1st quarter. NewEdge Advisors LLC now owns 23,788 shares of the company’s stock valued at $387,000 after acquiring an additional 3,562 shares during the period. WNY Asset Management LLC bought a new stake in shares of abrdn Life Sciences Investors during the 1st quarter valued at $239,000. Finally, Bank of America Corp DE grew its holdings in shares of abrdn Life Sciences Investors by 8.6% during the 1st quarter. Bank of America Corp DE now owns 115,585 shares of the company’s stock worth $1,881,000 after purchasing an additional 9,145 shares in the last quarter. Institutional investors and hedge funds own 32.21% of the company’s stock.

abrdn Life Sciences Investors Company Profile

abrdn Life Sciences Investors (NYSE: HQL) is a closed-end management investment company that seeks capital appreciation through investment in the life sciences sector. Established in 1994, the trust focuses on equity and equity-related securities of companies engaged in biotechnology, pharmaceuticals, medical devices, diagnostics and related fields. Its closed-end structure allows portfolio managers to maintain a stable pool of capital, pursue long-term investment strategies and employ leverage when deemed appropriate.

The fund’s portfolio spans both public and private companies, with an emphasis on businesses driving innovation in drug development, gene therapy, precision medicine and healthcare technology.